Allergan Receives Canadian Approval for Long Term Treatment with Fibristal

Allergan (NYSE:AGN) today announced that it has received further approval from Health Canada regarding FIBRISTAL: the drug can be used for intermittent treatment of uterine fibroids.
According to the press release:

“FIBRISTAL^® is the first and only non-surgical treatment specifically indicated to treat the signs and symptoms of uterine fibroids. In long term clinical studies FIBRISTAL^® was shown to safely and effectively control excessive uterine bleeding, shrink fibroid volume and reduce the significant pain and symptom severity scores associated with symptomatic uterine fibroids.”

Ed Gudaitis, General Manager of Allergan Canada, said the following:

“The approval of FIBRISTAL^® for long term intermittent use is an important step in changing the lives of Canadian women who live with this challenging condition and need a highly effective and safe medical therapy option.”

Read the full press release here.